Financial Statements Notes to the Company Financial Statements 1 Fixed asset investments Investments in subsidiaries Shares Loans Total $m $m $m At 1 January 2017 16,026 14,423 30,449 Additions 1,987 1,987 Transfer to current assets 1,399 1,399 Capital reimbursement 30 30 Exchange 463 463 Amortisation 12 12 At 31 December 2017 15,996 15,486 31,482 A list of subsidiaries is included on pages 190 to 193.
2 Non-trade creditors 2017 2016 $m $m Amounts due within one year Short-term borrowings 199 371 Other creditors 119 140 Amounts owed to Group undertakings 7 7 325 518 3 Loans Repayment 2017 2016 dates $m $m Amounts due within one year Interest-bearing loans and borrowings unsecured Floating rate notes US dollars 2018 399 1.75% Callable bond US dollars 2018 998 5.9% Callable bond US dollars 2017 1,749 1,749 1,397 Amounts due after more than one year Amounts owed to Group undertakings unsecured 7.2% Loan US dollars 2023 283 283 Interest-bearing loans and borrowings unsecured Floating rate notes US dollars 2018 399 1.75% Callable bond US dollars 2018 998 1.95% Callable bond US dollars 2019 999 998 2.375% Callable bond US dollars 2020 1,591 1,589 0.875% Non-callable bond euros 2021 890 782 0.25% Callable bond euros 2021 594 522 Floating rate bond US dollars 2022 249 2.375% Callable bond US dollars 2022 992 0.75% Callable bond euros 2024 1,067 937 3.375% Callable bond US dollars 2025 1,978 1,976 3.125% Callable bond US dollars 2027 742 1.25% Callable bond euros 2028 941 827 5.75% Non-callable bond pounds sterling 2031 468 426 6.45% Callable bond US dollars 2037 2,720 2,719 4% Callable bond US dollars 2042 987 986 4.375% Callable bond US dollars 2045 979 979 15,197 14,138 AstraZeneca Annual Report & Form 20-F Information 2017 Notes to the Company Financial Statements 197 Notes to the Company Financial Statements continued 3 Loans continued 2017 2016 $m $m Loans are repayable: After five years from balance sheet date 10,165 9,133 From two to five years 4,316 3,891 From one to two years 999 1,397 Within one year 1,397 1,749 Total unsecured 16,877 16,170 With the exception of the 2018 and 2022 floating rate notes, all loans are at fixed interest rates.
Accordingly, the fair values of the loans will change as market rates change.
However, since the loans are held at amortised cost, changes in interest rates and the credit rating of the Company do not have any effect on the Companys net assets.
4 Share capital Details of share capital movements in the year are included in Note 22 to the Group Financial Statements.
5 Contingent liabilities The Company is named as a party to legal proceedings in the Farxiga product liability litigation and the Array BioPharma Inc. commercial litigation, each of which are described more fully in Note 28 to the Group Financial Statements.
Other The Company has guaranteed the external borrowing of a subsidiary in the amount of $286m.
6 Statutory and other information The Directors were paid by another Group company in 2017 and 2016.
7 Subsequent events There were no material subsequent events.
198 AstraZeneca Annual Report & Form 20-F Information 2017 Financial Statements
